Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Recombinant broad-spectrum COVID-19 vaccine
- Development stage
- Preclinical
- Lead developer
- AIM Vaccine Co.
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The Recombinant broad-spectrum COVID-19 vaccine is a protein subunit vaccine candidate currently in preclinical development by AIM Vaccine Co. It is engineered using recombinant DNA technology to express antigens that elicit a broad immune response against multiple SARS-CoV-2 variants, including various variants of concern. This vaccine is part of AIM Vaccine's multi-platform R&D strategy, which aims to address viral evolution and the emergence of new strains by providing cross-reactive protection. It is designed to stimulate both neutralizing antibodies and cellular immunity to prevent COVID-19 infection across a wide range of viral lineages.
- Other names
- Broad-spectrum SARS-CoV-2 vaccineRecombinant broad-spectrum COVID-19 vaccineAIM Vaccine broad-spectrum COVID-19 vaccine
02
Targets
SARS-CoV-2 spike
Beyond the preview
Go deeper on Recombinant broad-spectrum COVID-19 vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Recombinant broad-spectrum COVID-19 vaccine.